Mizuta Toshihiko, Ozaki Iwata
Saga Medical School, Department of Internal Medicine.
Clin Calcium. 2007 Nov;17(11):1693-9.
Despite recent progress in diagnosis and therapy, hepatocellular carcinoma (HCC) remains among the cancers with the poorest prognoses. Vitamin K (VK) have been shown to suppress the growth of HCC cells. Long-term administration of VK(2) has established its clinical safety, but it does not appear to exhibit marked anti-tumor effects when administered alone. For more effective use of VK against HCC, co-administration of VK(2) with other proven anticancer agents or development of a new VK preparation with a modified side-chain should be investigated in the future.
尽管在诊断和治疗方面取得了最新进展，但肝细胞癌（HCC）仍然是预后最差的癌症之一。维生素K（VK）已被证明可抑制肝癌细胞的生长。长期服用VK（2）已证实其临床安全性，但单独使用时似乎并未表现出明显的抗肿瘤作用。为了更有效地利用VK对抗HCC，未来应研究将VK（2）与其他经证实的抗癌药物联合使用，或开发具有修饰侧链的新型VK制剂。
